The data exceeds my most optimistic expectations ..... the sample size is reduced from 28 patients down o 7 (if you consider LL and PD-1 blocker). The cure rate is close to 70%. If the combo is given when women first are diagnosed with Tnbc, I believe they will cure virtually all of the inflicted women. This is much better than LL curing 4/5 out of 28. The only thing that is bothersome is the FDA will demand further validation and not open the flood gates and let the women have the combo now.... Do a phase four in real-time monitor results as it happens
It's like football, pick up the fumble and run with it or be conservative and wrap it up to be sure of possession. I'm afraid the FDA will be conservative, and thousands of mothers will die needlessly while they make sure.